Дисфункция щитовидной железы у больных сахарным диабетом 2-го типа


Цитировать

Полный текст

Аннотация

Аннотация. Представлены современные данные о сочетании сахарного диабета 2-го типа и дисфункции щитовидной железы (ЩЖ), о развитии сосудистых осложнений, атерогенеза; оценено влияние терапии на течение обоих заболеваний. Указано на необходимость проводить ежегодное скрининговое обследование больных сахарным диабетом 2-го типа для выявления дисфункции ЩЖ.

Полный текст

Дисфункция щитовидной железы у больных сахарным диабетом 2-го типа. - Аннотация. Представлены современные данные о сочетании сахарного диабета 2-го типа и дисфункции щитовидной железы (ЩЖ), о развитии сосудистых осложнений, атерогенеза; оценено влияние терапии на течение обоих заболеваний. Указано на необходимость проводить ежегодное скрининговое обследование больных сахарным диабетом 2-го типа для выявления дисфункции ЩЖ.
×

Об авторах

И В Терещенко

ГБОУ ВПО "Пермская государственная медицинская академия им. акад. Е.И. Вагнера" Минздрава России

Email: i_v_t@bk.ru

А А Суслина

ГБОУ ВПО "Пермская государственная медицинская академия им. акад. Е.И. Вагнера" Минздрава России

Список литературы

  1. Сахарный диабет: диагностика лечение и профилактика. Под ред. И.И. Дедова, М.В. Шестаковой. М: МИА 2012: 20.
  2. Петунина Н.А. Болезни щитовидной железы. М: ГЭОТАР-МЕД 2011: 15.
  3. Hage M., Zantout M.S., Azar S.T. Thyroid disorders and diabetes mellitus. J Thyroid Res 2011; 2011: 439-463.
  4. Chubb S.A., Davis W.A., Inman Z., Davis T.M. Prevalence and progression of subclinical hypothyroidism in women with type 2 diabetes: the Fremantle Diabetes Study. Clin Endocrinol (Oxf) 2005; 62 (4): 480-486.
  5. Smithson M.J. Screening for thyroid dysfunction in a community population of diabetic patients. Diabet Med 1998; 15 (2): 148-150.
  6. Ashrafuzzaman S.M., Taib A.N., Rahman R., Latif Z.A. Prevalence of diabetes among hypothyroid subjects. Mymensingh Med J 2012; 21 (1): 129-132.
  7. Papazafiropoulou A., Sotiropoulos A., Kokolaki A. et al. Prevalence of thyroid dysfunction among greek type 2 diabetic patients attending an outpatient clinic. J Clin Med Res 2010; 2 (2): 75-78.
  8. Ishay A., Chertok-Shaham I., Lavi I., Luboshitzky R. Prevalence of subclinical hypothyroidism in women with type 2 diabetes. Med Sci Monit 2009; 15 (4): 151-155.
  9. Radaideh A.R., Nusier M.K., Amari F.L. et al. Thyroid dysfunction in patients with type 2 diabetes mellitus in Jordan. Saudi Med J 2004; 25 (8): 1046-1050.
  10. Demitrost L., Ranabir S. Thyroid dysfunction in type 2 diabetes mellitus: A retrospective study. Indian J Endocrinol Metab 2012; 16 (Suppl 2): 334-335.
  11. Diez J.J., Iglesias P. Subclinical hyperthyroidism in patients with type 2 diabetes. Endocrine 2012; 42 (1):157-163.
  12. Yang G.R., Yang J.K., Zhang L. et al. Association between subclinical hypothyroidism and proliferative diabetic retinopathy in type 2 diabetic patients: a case-control study. Tohoku J Exp Med 2010; 222 (4): 303-310.
  13. Tamez-Perez H.E., Martínez E., Quintanilla-Flores D.L. et al. The rate of primary hypothyroidism in diabetic patients is greater than in the non-diabetic population. An observational study. Med Clin (Barc) 2012; 138 (11): 475-477.
  14. Akbar D.H., Ahmed M.M., Al-Mughales J. Thyroid dysfunction and thyroid autoimmunity in Saudi type 2 diabetics. Acta Diabetol 2006; 43: 14-18.
  15. Johnson J.L. Diabetes Control in Thyroid Disease. Diabetes Spectrum 2006; 19 (3): 148-153.
  16. Wu P. Thyroid disorders and diabetes. It is common for a person to be affected by both thyroid disease and diabetes. Diabetes Self Manag 2007; 24 (5): 80-82, 85-87.
  17. Perros P., McCrimmon R.J., Shaw G., Frier B.M. Frequency of thyroid dysfunction in diabetic patients: value of annual screening. Diabet Med 1995; 12 (7): 622-627.
  18. Shih S.R., Chiu W.Y., Chang T.C., Tseng C.H. Diabetes and thyroid cancer risk: literature review. Exp Diabetes Res 2012; 5: 782-785.
  19. Балаболкин М.И. Дифференциальная диагностика и лечение эндокринных заболеваний. М: МИА 2008: 185-193.
  20. Thvilum M., Brandt F., Brix T.H., Hegedüs L. A review of the evidence for and against increased mortality in hypothyroidism. Nat Rev Endocrinol 2012; 8 (7): 417-424.
  21. Pasqualetti G., Tognini S., Polini A. et al. Is subclinical hypothyroidism a cardiovascular risk factor in the elderly? J Clin Endocrinol Metab 2013; 98 (6): 2256-2266.
  22. Mitu F., Cojocaru E., Tamba B., Leon M.M. Prevalence of cardiovascular diseases in patients with hypothyroidism. Rev Med Chir Soc Med Nat Iasi 2012; 116 (2): 413-418.
  23. Moura Neto A., Parisi M.C., Tambascia M.A. et al. Relationship of thyroid hormone levels and cardiovascular events in patients with type 2 diabetes. Endocrine 2013 Apr 2. [Epub ahead of print]
  24. Chen H.S., Wu T.E.J., Jap T.S. et al. Subclinical hypothyroidism is a risk factor for nephropathy and cardiovascular diseases in Type 2 diabetic patients. Diabetic Med 2007; 24 (12): 1336-1344.
  25. Сазонова Е.Г., Мохорт Т.В. Тиреоидная функция при сахарном диабете, осложненном хронической болезнью почек. Междунар эндокринол журн 2013; 2: 20-23.
  26. Ramis J.N., Artigas C.F., Santiago M.A. et al. Is there a relationship between TSH levels and diabetic retinopathy in the Caucasian population? Diabetes Res Clin Pract 2012; 97 (3): 45-47.
  27. Yang J.K., Liu W., Shi J., Li Y.B. An association between subclinical hypothyroidism and sight-threatening diabetic retinopathy in type 2 diabetic patients. Diabetes Care 2010; 33 (5): 1018-1020.
  28. Valentina V.N., Marijan B., Chedo D., Branka K. Subclinical hypothyroidism and risk to carotid atherosclerosis. Arq Bras Endocrinol Metabol 2011; 55 (7): 475-480.
  29. Cappola A.R., Ladenson P.W. Hypothyroidism and atherosclerosis. J Clin Endocrinol Metab 2003; 88 (6): 2438-2444.
  30. La Vignera S., Condorelli R., Vicari E., Calogero A.E. Endothelial dysfunction and subclinical hypothyroidism: a brief review. J Endocrinol Invest 2012; 35 (1): 96-103.
  31. Ichiki T. Thyroid hormone and atherosclerosis. Vascul Pharmacol 2010; 52 (3-4): 151-156.
  32. Kutluturk F., Yuce S., Tasliyurt T. et al. Changes in metabolic and cardiovascular risk factors before and after treatment in overt hypothyroidism. Med Glas (Zenica) 2013; 10 (2): 348-353.
  33. Sigal G.A., Medeiros-Neto G., Vinagre J.C. et al. Lipid metabolism in subclinical hypothyroidism: plasma kinetics of triglyceride-rich lipoproteins and lipid transfers to high-density lipoprotein before and after levothyroxine treatment. Thyroid 2011; 21 (4): 347-353.
  34. Kowalska I., Borawski J., Nikołajuk A. et al. Insulin sensitivity, plasma adiponectin and sICAM-1 concentrations in patients with subclinical hypothyroidism: response to levothyroxine therapy. Endocrine 2011; 40 (1): 95-101.
  35. Wang C. The Relationship between Type 2 Diabetes Mellitus and Related Thyroid Diseases. J Diabetes Res 2013; 2013: 390-413.
  36. Баранов В.Г., Оркодашвили Л.Ш. Болезни островкового аппарата поджелудочной железы. В кн: Руководство по клинической эндокринологии. Под ред. В.Г. Баранова. Л: Медицина 1977: 31-136.
  37. Терещенко И.В., Трефилова Е.С. Тиреоидная патология у больных сахарным диабетом. Сахарный диабет 2001; 4: 22-24.
  38. Ittermann T., Markus M.R., Schipf S. et al. Metformin inhibits goitrogenous effects of type 2 diabetes. Eur J Endocrinol 2013; 169 (1): 9-15.
  39. Cappelli C., Rotondi M., Pirola I. et al. Thyreotropin levels in diabetic patients on metformin treatment. Eur J Endocrinol 2012; 167 (2): 261-265.
  40. Casteràs A., Zafon C., Ciudin A., Mesa J. Are Levothyroxine Requirements Lower in Thyroidectomized Diabetic Patients on Metformin Treatment? Thyroid 2013 Sep 3. [Epub ahead of print]
  41. Diez J.J., Iglesias P. Relationship between serum thyrotropin concentrations and metformin therapy in euthyroid patients with type 2 diabetes. Clin Endocrinol (Oxf) 2013; 78 (4): 505-511.
  42. Kouidhi S., Berhouma R., Ammar M. et al. Relationship of thyroid function with obesity and type 2 diabetes in euthyroid Tunisian subjects. Endocr Res 2013; 38 (1): 15-23.
  43. Kitahara C.M., Platz E.A., Freeman L.E. et al. Obesity and thyroid cancer risk among U.S. men and women: a pooled analysis of five prospective studies. Cancer Epidemiol Biomark Prevent 2011; 20 (3): 464-472.
  44. Renehan A.G., Tyson M., Egger M. et al. Body-mass index and incidence of cancer: a systematic review and meta-analysis of prospective observational studies. Lancet 2008; 371 (9612): 569-578.
  45. Uddin S., Bavi P., Siraj A.K. et al. Leptin-R and its association with PI3K/AKT signaling pathway in papillary thyroid carcinoma. Endocrine-Related Cancer 2010; 17 (1): 191-202.
  46. Currie C.J., Poole C.D., Gale E.A. The influence of glucose-lowering therapies on cancer risk in type 2 diabetes. Diabetologia 2009; 52 (9): 1766-1777.
  47. Chen G., Xu S., Renko K., Derwahl M. Metformin inhibits growth of thyroid carcinoma cells, suppresses self-renewal of derived cancer stem cells, and potentiates the effect of chemotherapeutic agents. J Clin Endocrinol Metab 2012; 97 (4): 510-520.
  48. Klubo-Gwiezdzinska J., Costello J.Jr., Patel A. et al. Treatment with metformin is associated with higher remission rate in diabetic patients with thyroid cancer. J Clin Endocrinol Metab 2013; 98 (8): 3269-3279.
  49. Currie C.J., Poole C.D., Gale E.A. The influence of glucose-lowering therapies on cancer risk in type 2 diabetes. Diabetologia 2009; 52 (9): 1766-1777.
  50. Tahrani A.A., Ball A., Shepherd L. et al. The prevalence of vitamin D abnormalities in South Asians with type 2 diabetes mellitus in the UK. Intern J Clin Pract 2010; 64 (3): 351-355.
  51. Aschebrook-Kilfoy B., Sabra M.M., Brenner A. et al. Diabetes and thyroid cancer risk in the National Institutes of Health-AARP Diet and Health study. Thyroid 2011; 21 (9): 957-963.
  52. Knudsen L.B., Madsen L.W., Andersen S. et al. Glucagon-like peptide-1 receptor agonists activate rodent thyroid C-cells causing calcitonin release and C-cell proliferation. Endocrinology 2010; 151 (4): 1473-1486.
  53. Madsen L.W., Knauf J.A., Gotfredsen C. et al. GLP-1 receptor agonists and the thyroid: C-cell effects in mice are mediated via the GLP-1 receptor and not associated with RET activation. Endocrinology 2012; 153 (3): 1538-1547.
  54. Gallo M. Thyroid safety in patients treated with liraglutide. J Endocrinol Invest 2013; 36 (2): 140-145.
  55. Drucker D.J., Sherman S.I., Bergenstal R.M., Buse J.B. The safety of incretin-based therapies-review of the scientific evidence. J Clin Endocrinol Metab 2011; 96 (7): 2027-2031.
  56. Handelsman Y., Leroith D., Bloomgarden Z.T. et al. Diabetes and Cancer - an AACE/ACE Consensus statement. Endocr Pract 2013; 19 (4): 675-693.
  57. Melville N.A. Hypothyroidism Shows Strong Association with Type 2 Diabetes, Screening Recommended. American Association of Clin. Endocrinologists (AACE) www.docguide.com/hypothyroidism-shows-strong-association-type-2-diabetes-screening-recommended
  58. Kadiyala R., Peter R., Okosieme O.E. Thyroid dysfunction in patients with diabetes: clinical implications and screening strategies. Int J Clin Pract 2010; 64 (8): 1130-1139.

Дополнительные файлы

Доп. файлы
Действие
1. JATS XML
Скачать

© ООО "Консилиум Медикум", 2014

Creative Commons License
Эта статья доступна по лицензии Creative Commons Attribution-NonCommercial-ShareAlike 4.0 International License.
 

Адрес издателя

  • 127055, г. Москва, Алабяна ул., 13, корп.1

Адрес редакции

  • 127055, г. Москва, Алабяна ул., 13, корп.1

По вопросам публикаций

  • +7 (926) 905-41-26
  • editor@ter-arkhiv.ru

По вопросам рекламы

  • +7 (495) 098-03-59

 

  


Данный сайт использует cookie-файлы

Продолжая использовать наш сайт, вы даете согласие на обработку файлов cookie, которые обеспечивают правильную работу сайта.

О куки-файлах